Stockreport

Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]

Revolution Medicines, Inc.  (RVMD) 
PDF R&D Expenses: $262.5 million for Q3 2025, up from $151.8 million in Q3 2024. G&A Expenses: $52.8 million for Q3 2025, up from $24.0 million in Q3 2024. Net Loss: $3 [Read more]